

## DAFTAR PUSTAKA

1. Haryani S, Defrin, Yenita. Prevalensi Kanker Serviks Berdasarkan Paritas di RSUP. Dr. M. Djamil Padang Periode Januari 2011- Desember 2012. *J Kesehat Andalas*. 2016;5(3):647–52.
2. Jean Damascène Makuza, Sabin Nsanzimana, Marie Aimee Muhimpundu, Lydia Eleanor Pace, Joseph Ntaganira DJR. Prevalence and risk factors for cervical cancer and pre-cancerous lesions in Rwanda. *Pan Afr Med J*. 2015;22(26):1–8.
3. Bruni L, Barrionuevo-Rosas L, Alberto G, Serrano B, Mena M, Gómez D, et al. *Human Papillomavirus and Related Diseases Report*. Barcelona; 2017.
4. Mishra GA, Pimple SA, Shastri SS. Prevention of Cervix Cancer in India. *Karger*. 2016;91(1):1–7.
5. Kementrian Kesehatan RI. *Situasi Penyakit Kanker*. Riset Kesehatan Dasar. 2015.
6. Dinas Kesehatan Provinsi Sumatera Barat. *Profil Kesehatan Provinsi Sumatera Barat 2014*. Kesehatan. Padang; 2015.
7. Yanti YN. Gambaran Faktor Resiko Kejadian Kanker Serviks di RSUP Dr. M. Djamil Padang. *J Kesehat Andalas*. 2018;1–17.
8. Deverakonda A, Gupta N. Diagnosis and treatment of cervical cancer: a review. *J Nurs Heal Sci*. 2016;2(3):1–11.
9. Marth C, Landoni F, Mahner S, McCormack M, Gonzalez-Martin A, Colombo N. Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2017;28(4):72–83.
10. Lapresa M, Parma G, Portuesi R, Colombo N. Neoadjuvant chemotherapy in cervical cancer: An update. *Expert Rev Anticancer Ther*. 2015;15(10):1171–81.
11. Iwata T, Miyauchi A, Suga Y, Nishio H, Nakamura M, Ohno A, et al. Neoadjuvant chemotherapy for locally advanced cervical cancer. *Chinese J Cancer Res*. 2016;28(2):235–40.
12. González-Martín A, González-Cortijo L, Carballo N, Garcia JF, Lapuente F, Rojo A, et al. The current role of neoadjuvant chemotherapy in the

- management of cervical carcinoma. *Gynecol Oncol.* 2008;110:36–40.
13. Loizzi V, Vecchio V Del, Crupano FM, Minicucci V, Fumarulo V V, Resta L, et al. A phase II study: dose-dense carboplatin and paclitaxel as neoadjuvant chemotherapy in locally advanced cervical cancer A phase II study: dose-dense carboplatin and paclitaxel as neoadjuvant chemotherapy in locally advanced cervical cancer. *J Chemother.* 2018;30(4):247–52.
  14. Testa AC, Ferrandina G, Distefano M, Fruscella E, Mansueto D, Basso D, et al. Color Doppler velocimetry and three-dimensional color power angiography of cervical carcinoma. *Ultrasound Obstet Gynecol.* 2004;24(4):445–52.
  15. Alldredge JK, Tewari KS. Clinical Trials of Antiangiogenesis Therapy in Recurrent/Persistent and Metastatic Cervical Cancer. *Oncologist.* 2016;21(5):576–85.
  16. Mangla M, Singla D. Transvaginal colour Doppler ultrasound in predicting response to chemoradiation in patients with carcinoma of the cervix. *South African J Gynaecol Oncol.* 2015;7(2):68–71.
  17. Epstein E, Di Legge A, Måsbäck A, Lindqvist PG, Kannisto P, Testa AC. Sonographic characteristics of squamous cell cancer and adenocarcinoma of the uterine cervix. *Ultrasound Obstet Gynecol.* 2010;36(4):512–6.
  18. Belitsos P, Papoutsis D, Rodolakis A, Mesogitis S, Antsaklis A. Three-dimensional power Doppler ultrasound for the study of cervical cancer and precancerous lesions. *Ultrasound Obstet Gynecol.* 2012;40(5):576–81.
  19. Hsu KF, Su JM, Huang SC, Cheng YM, Kang CY, Shen MR, et al. Three-dimensional power Doppler imaging of early-stage cervical cancer. *Ultrasound Obstet Gynecol.* 2004;24(6):664–71.
  20. Onofrio AD, Gandolfi A. Chemotherapy of vascularised tumours: Role of vessel density and the effect of vascular "pruning". *J Theor Biol.* 2010;264(2):253.
  21. Kementrian Kesehatan RI. Pedoman Nasional Pelayanan Kedokteran Kanker Serviks. Komite Penanggulangan Kanker Nasional. Jakarta; 2017.
  22. Rasjidi I. Epidemiologi Kanker Serviks. *Indones J Cancer.* 2009;3(3):103–8.

23. Shepherd JH. Cervical cancer Guideline. *Eur Soc Gynaecol Oncol.* 2012;26(3):293–309.
24. Chabra S. Cervical Cancer Preventable , Treatable , but Continues to Kill Women. *Cerv Cancer.* 2016;1(3):1–2.
25. El-Moselhy EA, Borg HM AS. Cervical Cancer: Sociodemographic and Clinical Risk Factors among Adult Egyptian Females. *Adv Oncol Res Treat.* 2016;1(1):7.
26. Ginsburg OM. Breast and cervical cancer control in low and middle-income countries: Human rights meet sound health policy. *J Cancer Policy.* 2013;1(3–4):35–41.
27. Saleh HS. Can visual inspection with acetic acid be used as an alternative to Pap smear in screening cervical cancer? *Middle East Fertil Soc J.* 2014;19(3):187–91.
28. Widiastuti NMR, Witati JDMS. Delay of early detection on cervical cancer patients advance stadium in Sanglah central hospital Denpasar. *Int J Res Med Sci.* 2018;6(6):1867–70.
29. Subagio S. Hubungan Faktor Risiko dengan Derajat Histopatologi Kanker Serviks di RSUD Dr. H. Abdul Moeloek Bandar Lampung Tahun 2015-2016. Lampung; 2017.
30. Wulandari V. Hubungan Faktor Risiko Penggunaan Kontrasepsi Oral dan Aktivitas Seksual dengan Kejadian Kanker Serviks. *J Berk Epidemiol.* 2016;4(3):432–443.
31. Hidayat, E, Hasibuan, D.H.S, Fitriyati Y. Hubungan Kejadian Kanker Serviks dengan Jumlah Paritas di RSUD DR. Moewardi Tahun 2013. *J Kedokt dan Kesehat Indones.* 2013;6(3):128–36.
32. Damayanti IP. Faktor-faktor yang Berhubungan dengan Kejadian Kanker Serviks di RSUD Arifin Achmad Pekanbaru Tahun 2008-2010. *J Kesehat Komunitas.* 2013;2(2):88–93.
33. Darmawati. Kanker Serviks Wanita Usia Subur. *Idea Nurs J.* 2007;1(1):9–14.
34. Momenimovahed Z, Salehiniya H. Incidence , mortality and risk factors of cervical cancer in the world. *Biomed Res Ther.* 2017;4(12):1795–811.

35. Wulandari AS. Pengertian dan Pemahaman Resiko CA Cervix pada Wanita Usia Subur di Indonesia. *J Promkes*. 2016;2(1):58–65.
36. Amin Y, Mulawardhana P, Erawati D. Demografi , Respon Terapi dan Survival rate Pasien Kanker Serviks Stadium III-IVA yang Mendapat Kemoterapi Dilanjutkan Radioterapi. *Maj Obstet Ginekol*. 2015;23(3):97–105.
37. Lax S. Histopathology of cervical precursor lesions and cancer. *Acta Dermatovenerologica Alpina, Pannonica Adriat*. 2011;20(3):125–33.
38. Setiawati D. Human Papilloma Virus Dan Kanker Serviks. *Public Heal Sci J*. 2014;6(2):450–9.
39. Supraptiwi Rahayu A. Inveksi Human Papilloma Virus (HPV) dan Pencegahannya pada Remaja dan Dewasa Muda. *J Biol Papua*. 2010;2(2):81–8.
40. Aubuchon M, Burney RO, Schust DJ, Yao MWM. Reproductive Endocrinology. *Berek & Novak’s Gynecology*. 2015. 1965-2044 p.
41. Schiller W. Pathology of the cervix. Herrington CS, editor. Vol. 34, *American Journal of Obstetrics and Gynecology*. Springer; 2017. 430-438 p.
42. CI A, NE M, PO E. Cervical Cancer: A Health Limiting Condition. *Gynecol Obstet*. 2016;06(05):1–7.
43. Aldhafar AS, Alhulaybi AA, Khan TM. Knowledge, Early Signs and Symptoms, Risk Factors and Prevention of Cervical Cancer among Teachers in the Urban Schools in Al-Ahsa, Kingdom of Saudi Arabia. *Int J Sci Study*. 2016;4(3):73–6.
44. Setyarini E. Faktor - Faktor yang Berhubungan dengan Kejadian Kanker Leher Rahim di RSUD DR. Moewardi Surakarta. Muhammadiyah Surakarta; 2009.
45. Su Y, Du L, Wu Y, Zhang J, Zhang X, Jia X, et al. Evaluation of cervical cancer detection with acoustic radiation force impulse ultrasound imaging. *Exp Ther Med*. 2013;5(6):1715–9.
46. Faradina D. Histerektomi Radikal Pada Kanker Serviks Di RSUP.H.Adam Malik Medan Januari 2002 – Desember 2006. Sumatera Utara; 2009.
47. Osman M. The role of neoadjuvant chemotherapy in the management of

locally advanced cervix cancer : a systematic review co m m er ci al us e on  
co m m er ci al us e. 2014;8.

48. Cetina L, Rivera L, Mariscal I, Montalvo G, Gómez E, Garza J De, et al. Original article A phase II study of multimodality treatment for locally advanced cervical cancer : neoadjuvant carboplatin and paclitaxel followed by radical hysterectomy and adjuvant cisplatin chemoradiation. 2003;1278–84.
49. Tirkes T, Hollar MA, Tann M, Kohli MD, Akisik F, Sandrasegaran K. Response Criteria in Oncologic Imaging: Review of Traditional and New Criteria. *RadioGraphics*. 2013;33(5):1323–41.
50. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). *Eur J Cancer*. 2009;45(2):228–47.
51. Ades F, Yamaguchi N. WHO, RECIST, and immune-related response criteria: Is it time to revisit pembrolizumab results? *Ecancermedicalsecience*. 2015;9(604):1–4.
52. Shirali E, Yarandi F, Behtash N, Hemmatian O. Neoadjuvant Chemotherapy in Cervical Cancer : A Review Article. *J Obstet Gynecol Cancer Res*. 2018;3(2):87–91.
53. Kyung MS, Kim HB, Seoung JY, Choi INY, Joo YSOO, Lee MEY, et al. Tumor size and lymph node status determined by imaging are reliable factors for predicting advanced cervical cancer prognosis. *Int J Gynecol Cancer*. 2014;24(9):1–7.
54. Yuh WTC, Wang JZ, Wu DH, Montebello JF, Meeks SL, Paulino AC, et al. Serial Therapy-Induced Changes in Tumor Shape in Cervical Cancer and Their Impact on Assessing Tumor Volume and Treatment Response. *AJR*. 2006;187:65–72.
55. Fuso L, Mazzola S, Marocco F, Ferrero A, Dompe D, Carus AP, et al. Pretreatment serum hemoglobin level as a predictive factor of response to neoadjuvant chemotherapy in patients with locally advanced squamous cervical carcinoma : A preliminary report. *Gynecol Oncol*. 2005;99:187–91.
56. Khatun S, Noor-E-Ferdous, Sharmin F, Ferdous J, Goodman A. Role of

- Neoadjuvant Chemotherapy in Treatment of Cervical Cancer : A Case Series of Thirty-Eight Patients Treated at Bangabandhu Sheikh Mujib Medical University in Dhaka , Bangladesh. *Obstet Gynecol.* 2018;8:446–55.
57. Alcázar JL, Jurado M, Lopez-García G. Tumor vascularization in cervical cancer by 3-dimensional power Doppler angiography correlation with tumor characteristics. *Int J Gynecol Cancer.* 2010;20(3):393–7.
  58. Hapsari BK. Hubungan Antara Cell Death Dengan Vaskularisasi Dan Reaksi Limfosit Pada Kanker Serviks Jenis Squamous Cell Carcinoma. 2015;1(2):112–6.
  59. Zhu P, Ou Y, Dong Y, Xu P, Yuan L. Expression of VEGF and HIF-1 $\alpha$  in locally advanced cervical cancer: potential biomarkers for predicting preoperative radiochemotherapy sensitivity and prognosis. *Onco Targets Ther.* 2016;9:3031–7.
  60. Tomao F, Papa A, Rossi L, Zaccarelli E, Caruso D, Zoratto F, et al. Angiogenesis and antiangiogenic agents in cervical cancer. *Onco Targets Ther.* 2014;7:2237–48.
  61. Bates J. *Practical Gynaecological Ultrasound.* Second Edi. Jane Bates, MPhil, DMU D, editor. Cambridge: Cambridge University Press; 2006.
  62. Júnior EA. *Advanced Topics on Three-dimensional Ultrasound in Obstetrics and Gynecology* Edited by. 2016.
  63. Dahlan MS. *Besar Sampel dan Cara Pengambilan Sampel dalam Penelitian Kedokteran dan Kesehatan.* Vol. 3, Salemba Medika. 2010. 46-60 p.
  64. Qin J, Cheng X, Chen X, Zhang X, Lu W, Xie X. Value of three-dimensional power Doppler to predict clinical and histological response to neoadjuvant chemotherapy in locally advanced cervical carcinoma. 2012;310006(1):226–34.
  65. Wolchok JD, Hoos A, Day SO, Weber JS, Hamid O, Lebbé C, et al. Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors : Immune-Related Response Criteria. 2009;15(23):7412–20.
  66. Herlana F, Nur IM, Purbaningsih W. Karakteristik Pasien Kanker Serviks berdasar atas Usia , Paritas , dan Gambaran Histopatologi di RSUD Al-Ihsan Bandung Characteristics of Cervical Cancer Patients base on Age , Parity ,

- and Histopathologic Pattern in Al-Ihsan Bandung Regional Hospital. 2017;1(22):138–42.
67. Ningsih DPS, Pramoni D, Nurdianti DS. Faktor-faktor yang berhubungan dengan kejadian kanker serviks di RSUP Dr. Sardjito Yogyakarta. *Ber Kedokt Masy.* 2017;33(3).
  68. Fajriah RA. Distribusi Gambaran Histopatologi Pasien Kanker Serviks Uteri di RSUD Dr. Zainoel Abidin Banda Aceh. 2013;13:1–5.
  69. Hidayat,E, Hasibuan,D.H.S, Fitriyati Y. Hubungan Kejadian Kanker Serviks Dengan Jumlah. *Jkki.* 2013;6:128–36.
  70. Achmadi, T BA, Suhatno. Karakteristik Penderita Kanker Serviks 2006-2010 di RSUD dr. Soetomo. *Maj Obstet Ginekol.* 2011;19(3):128–33.
  71. Couvreur K, Naert E, Jaeghere E De, Tummers P, Makar A, Visschere P De, et al. Neo-adjuvant treatment of adenocarcinoma and squamous cell carcinoma of the cervix results in significantly different pathological complete response rates. 2018;1–10.
  72. Taneja A, Rajaram S, Agarwal S, Singh KC, Sahni S, Goel N. “Quick Cycle” neoadjuvant chemotherapy in squamous cell carcinoma of cervix. *Indian J Pharmacol.* 2005;37(5):320–4.
  73. Nuranna L, Prastasari R, Sutrisna B. Survival of cervical cancer patients and its prognostic factors at Cipto Mangunkusumo Hospital , Jakarta. 2014;23(3):163–8.
  74. Endo D, Todo Y, Okamoto K, Minobe S, Kato H, Nishiyama N. Prognostic factors for patients with cervical cancer treated with concurrent chemoradiotherapy : a retrospective analysis in a Japanese cohort. *J Gynecol Oncol.* 2014;26(1):12–8.
  75. Bogani G, Ditto A, Martinelli F, Signorelli M, Chiappa V, Lopez C, et al. Impact of Blood Transfusions on Survival of Locally Advanced Cervical Cancer Patients Undergoing Neoadjuvant Chemotherapy Plus Radical Surgery. 2017;27(3):514–22.
  76. Thakur P, Seam RK, Gupta MK, Gupta M, Bhattacharyya T, Sharma M. Comparison of Effects of Hemoglobin Levels Upon Tumor Response among Cervical Carcinoma Patients Undergoing Accelerated Hyperfractionated

- Radiotherapy versus Cisplatin Chemoradiotherapy. 2015;16:4285–9.
77. Fitri N. Pengaruh kadar hemoglobin, kadar hematokrit dan transfusi terhadap respon tumor dan kesintasan penderita kanker serviks stadium lanjut lokal. 2014;(September).
78. Uma S, Neetu A, Anju R. The Efficacy and Safety of Neoadjuvant Chemotherapy in Treatment of Locally Advanced Carcinoma Cervix. 2013;
79. Mandiæ A. Neoadjuvant chemotherapy in treatment of cervical cancer - controversies. 2005;13(2):89–90.
80. Marth C, Sundfor K, Kaern J, Trope C, Marth C, Sundfor K, et al. Long-term Follow-up of Neoadjuvant Cisplatin and 5-Fluorouracil Chemotherapy in Bulky Squamous Cell Carcinoma of the Cervix Long-term Follow-up of Neoadjuvant Cisplatin and 5-Fluorouracil Chemotherapy in Bulky Squamous Cell Carcinoma of the Cervix. 2009;
81. Rustin G, Jones B, Dina R. Use of neoadjuvant chemotherapy prior to radical hysterectomy in cervical cancer: monitoring tumour shrinkage and molecular profile on magnetic resonance and assessment of 3-year outcome Clinical. 2004;2:2326–31.
82. Dodampahala SH, Jayakody SN, Gunathilake WCC, Rahubaddha AN, Dodampahala SK. Transvaginal Color Doppler in the Assessment of Cervical Carcinoma and Pre-Cancer : Evidence from a Case Control Study Using Colour Doppler Ultrasonography Pulsatility Index of Uterine Vasculature. 2016;(August):93–9.
83. Muhammad S, Suardi D, Tobing MDL. Hubungan gambaran spektral pulse wave doppler dengan respon klinis terapi radiasi eksternal pada kanker serviks stadium IIB-IVA. Maj Kedokt Andalas. 2018;41(1):10–21.
84. Greco P, Cormio G, Vimercati A, Nacci G, Vagno G Di, Loverro G, et al. Transvarrinal color Doppler ultrasound for monitoring the response to neoadjuvant chemotherapy in advanced cervical cancer. Acta Obstet Gynecol Scand. 1997;76(2):169–72.
85. Chen C-A, Cheng W-F, Lee C-N, Su Y-N, Hsieh C-Y, Hsieh F-J. Power Doppler vascularity index for predicting the response of neoadjuvant chemotherapy in cervical carcinoma. Acta Obstet Gynecol Scand.



2004;83:591–7.

86. Nishida N, Yano H, Nishida T, Kamura T, Kojiro M. Angiogenesis in cancer. *Vasc Health Risk Manag.* 2006;2(3):213–9.
87. Santoso C, Askandar B. Keberhasilan Kemoterapi Neoajuvan Cisplatin-Vincristine-Bleomycin dan Paclitaxel-. *Maj Obstet Ginekol.* 2011;19(3).
88. Fischetti M, Musella A, Di V, Giorgia D. Dose-Dense Neoadjuvant Chemotherapy plus Radical Surgery in Locally Advanced Cervical Cancer : A Phase II Study. 2015;103–10.

